Nephrol Dial Transplant (2001) 16: 459-468
© 2001 European Renal Association-European Dialysis and Transplant Association
Special Feature
Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment
1 Azienda Ospedale di Lecco, Ospedale A. Manzoni, Lecco, Italy, and 2 University Hospital, Heidelberg, Germany, 3 Hôpital Manhes, Ste Geneviève des Bois, France, 4 Hospital Reina Sofia, Córdoba, Spain, 5 University Hospital Würzburg, Germany, 6 The Royal London Hospital, London, UK, 7 Reggio Cal Hospital, Reggio Calabria, Italy
Abstract
Introduction. Cardiovascular disease (CVD), as the leading cause of morbidity and mortality in patients on renal replacement therapy (RRT), has a central role in everyday nephrological practice.
Methods. Consensus was reached on key points relating to the clinical approach and treatment of the main cardiovascular risk factors in RRT patients (hypertension, anaemia, hyperparathyroidism, dyslipidaemia, new emerging risk factors). In addition, the role of convective treatments on cardiovascular outcomes was examined.
Results. Hypertension should be managed by aiming at blood pressure values of 
140/90 mmHg (160/90 mmHg in the elderly), firstly by ensuring target dry body weight is achieved. No single class of drug has proved superior to others in RRT patients, provided that the blood pressure target is achieved, although ACE inhibitors have shown specific organ protection in high-risk patients (HOPE study) and are well tolerated. Anaemia should be managed by using erythropoietin and iron supplements, aiming at haemoglobin levels of 12 g/dl and keeping serum ferritin levels <500 ng/ml. The management of hyperparathyroidism is currently unsatisfactory, as calcium supplements have the potential to increase cardiovascular calcification. While awaiting new calcium- and aluminium-free phosphate binders, it is essential to ensure dialysis adequacy. Clinical studies are in progress to assess the real impact of lipid-lowering drugs in RRT. In the meantime, serum LDL-cholesterol <160 mg/dl and triglycerides <500 mg/dl may be desirable targets. The impact of new emerging risk factors (inflammation and chronic infection, hyperhomocysteinaemia, metabolic waste-product accumulation) and their proper management are still under research. Convective dialysis treatments may confer some degree of protection from dialysis-related amyloidosis and mortality, but clinical data on this important issue are still controversial and no definitive conclusions can be drawn at present.
Conclusion. CVD prevention and treatment is a great challenge for the nephrologist. Achieving evidence-based consensus can help in encouraging the implementation of best clinical practice in line with the progress of current knowledge.
Keywords: anaemia; cardiovascular disease; convective treatments; dyslipidaemia; hyperparathyroidism; hypertension
Notes
Correspondence and offprint requests to: Prof. Dr Francesco Locatelli, Department of Nephrology and Dialysis, Ospedale A. Manzoni, Via Dell'Eremo 11, 23900 Lecco, Italy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Talmor-Barkan, G. Rashid, I. Weintal, J. Green, J. Bernheim, and S. Benchetrit Low extracellular Ca2+: a mediator of endothelial inflammation Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3306 - 3312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. de Jager, D. C. Grootendorst, K. J. Jager, P. C. van Dijk, L. M. J. Tomas, D. Ansell, F. Collart, P. Finne, J. G. Heaf, J. De Meester, et al. Cardiovascular and Noncardiovascular Mortality Among Patients Starting Dialysis JAMA, October 28, 2009; 302(16): 1782 - 1789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tepel, W. Hopfenmueller, A. Scholze, A. Maier, and W. Zidek Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3605 - 3612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Craig and J. M. Hunter Recent developments in the perioperative management of adult patients with chronic kidney disease Br. J. Anaesth., September 1, 2008; 101(3): 296 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Schiffrin, M. L. Lipman, and J. F.E. Mann Chronic Kidney Disease: Effects on the Cardiovascular System Circulation, July 3, 2007; 116(1): 85 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yildiz, E. Memisoglu, H. Oflaz, H. Yazici, H. Pusuroglu, V. Akkaya, F. Erzengin, and S. Tepe Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic haemodialysis patients Nephrol. Dial. Transplant., April 1, 2005; 20(4): 760 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Papagianni, E. Kokolina, M. Kalovoulos, A. Vainas, C. Dimitriadis, and D. Memmos Carotid atherosclerosis is associated with inflammation, malnutrition and intercellular adhesion molecule-1 in patients on continuous ambulatory peritoneal dialysis Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1258 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Amin, A. Fawzy, M. A. Hamid, and A. Elhendy Pulmonary Hypertension in Patients With Chronic Renal Failure: Role of Parathyroid Hormone and Pulmonary Artery Calcifications Chest, December 1, 2003; 124(6): 2093 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Oh, R. Wunsch, M. Turzer, M. Bahner, P. Raggi, U. Querfeld, O. Mehls, and F. Schaefer Advanced Coronary and Carotid Arteriopathy in Young Adults With Childhood-Onset Chronic Renal Failure Circulation, July 2, 2002; 106(1): 100 - 105. [Abstract] [Full Text] [PDF]
|
|